In this piece, we discuss the 10 Under-the-Radar Stocks with Massive Upside for 2026.
The earnings season, which carried equities to record highs, is largely over. Instead, the considerably less friendly macro environment is now taking center stage.
As of May 22, 2026, the S&P 500 stood close to its all-time high, up more than 9% for the year after eight consecutive weekly gains, per Reuters. But the backdrop is shifting fast.
The benchmark 10-year Treasury yield hit its highest level since January 2025 that same week, while the 30-year yield briefly touched its highest since 2007, Reuters reported. Inflation concerns are driving that move, compounded by energy price spikes tied to the U.S.-Israel conflict with Iran, which has effectively shut the Strait of Hormuz, a waterway that previously handled about one-fifth of global oil and LNG shipments.
Futures markets, which at the start of 2026 were pricing in rate cuts, are now fully pricing in a 25-basis-point Federal Reserve rate hike by January 2027, per Reuters on May 25, 2026. U.S. consumer sentiment fell to a record low in May as surging gasoline prices deepened affordability concerns.
In that environment, stock selection matters more than ever. Therefore, we will dive into our list of under-the-radar stocks with massive upside for 2026.
Phone with a stock chart
Our Methodology
To curate our list for this article, we screened for stocks with a market capitalization of over $2 billion and upside potential of at least 50%. Next, we considered hedge fund ownership of these stocks, selecting those with relatively fewer hedge fund holders than their industry peers, indicating they are under the radar. For hedge fund data, we relied on Insider Monkey’s hedge fund database, which tracks over 1,000 hedge funds as of Q4 2025.
Our list is presented in ascending order by each stock’s upside potential. Furthermore, our final selection is limited to stocks with noteworthy recent developments.
Note: All data sourced on May 26, 2026.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10. CRISPR Therapeutics AG (NASDAQ:CRSP)
With an analyst consensus upside of 52.3%, CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the under-the-radar stocks with massive upside for 2026.
As CASGEVY reinforced confidence in the company’s long-term growth outlook, CRISPR Therapeutics AG received fresh support from Wall Street.
On May 13, 2026, Bernstein raised its price target on CRISPR Therapeutics AG to $56 from $50 while keeping a “Market Perform” rating. The firm pointed to a strong start for biotech in 2026, with the sector up 11% year-to-date and outperforming both pharma and the S&P 500. Bernstein maintained a positive view on the space, citing expectations for healthy M&A and IPO activity and characterizing recent FDA leadership changes as a tailwind, particularly for less mature companies.
That update followed Q1 2026 results reported on May 4, 2026.
CASGEVY, the company’s approved gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia (TDT), generated $43 million in revenue during the quarter, with more than 500 patients having initiated treatment worldwide. Net loss narrowed to $122.9 million, or $1.28 per share, from $136.0 million a year earlier. R&D expenses came in at $68.6 million and G&A at $17.2 million, both lower than the prior-year period.
Cash, cash equivalents, and marketable securities strengthened to $2.44 billion as of March 31, 2026, up from $1.98 billion at year-end 2025, driven largely by $585.4 million in net proceeds from convertible senior notes issued in March. CEO Samarth Kulkarni said 2026 “will be a defining year” for CRISPR Therapeutics AG, citing pipeline milestones ahead.
Meanwhile, on May 5, 2026, BofA trimmed its price target to $83 from $86 but kept a “Buy” rating, saying the Q1 updates left its core thesis largely unchanged.
Overall, 14 out of 26 covering analysts hold bullish views on CRISPR Therapeutics AG.
CRISPR Therapeutics AG develops gene-editing therapies for serious diseases using its CRISPR/Cas9 platform technology.
9. Karman Holdings Inc. (NYSE:KRMN)
Karman Holdings Inc. (NYSE:KRMN), with upside potential of 66.9%, ranks among the under-the-radar stocks with massive upside for 2026.
While Karman Holdings Inc. closed a major acquisition and hit record revenue, analysts view the stock as one of the better-positioned players in the defense and space market.
On May 20, 2026, KeyBanc cut its price target on Karman Holdings Inc. to $100 from $122 while keeping an “Overweight” rating. Analyst Michael Leshock said the reduction reflects incrementally higher near-term investments and integration costs following Q1 results, though the firm’s long-term thesis remains intact.
“We believe KRMN is well-positioned to capitalize on the replenishment of missile inventories, growing investment in commercial/gov’t space programs, a strong A&D backdrop, and potential M&A opportunities,” Leshock said.
A day earlier, on May 19, 2026, Piper Sandler analyst Clarke Jeffries also trimmed the firm’s price target to $114 from $127, keeping an “Overweight” rating. Jeffries noted results were solid following the closeout of the Seemann and MSC deal, with the newly added Maritime Defense segment contributing 17% of revenue in the quarter. Piper continues to see Karman Holdings Inc. as well-positioned for both domestic and international munitions replenishment and for emerging categories, including hypersonics, space, and launch, with back-half contracts expected to flow into fiscal 2027 numbers and beyond.
Those analyst updates followed Q1 2026 results reported on May 12, 2026. Revenue came in at $151.2 million, up 51% year-over-year, with net income of $7.8 million, improving sharply from a $4.8 million loss a year earlier. Gross margin improved to 42.2%, and backlog reached a record $1.0 billion. For full-year 2026, Karman Holdings Inc. guided for revenue of $720 to $735 million and adjusted EBITDA of $208.5 to $219.5 million.
The Seemann and MSC acquisition, closed on February 3, 2026, added the Maritime Defense Systems end market. Karman expects to complete integration by the end of 2026. Seemann Composites and MSC are leaders in specialty maritime defense technologies.
Karman Holdings Inc. is an aerospace & defense company that deals in mission-critical systems in the U.S. The company supplies products for hypersonic systems, strategic missile defense, tactical & integrated defense, and space & launch markets.
8. NIQ Global Intelligence plc (NYSE:NIQ)
With an analyst consensus upside of 66.7%, NIQ Global Intelligence plc (NYSE:NIQ) ranks among the under-the-radar stocks with massive upside for 2026.
NIQ Global Intelligence plc (NYSE:NIQ) shares fell 18.3% on May 14, 2026, following the company’s earnings release, drawing three analyst price target cuts in the days after, even as each firm kept a bullish rating on the stock. The stock is down nearly 50% year-to-date.
On May 18, 2026, BMO Capital lowered its price target on NIQ Global Intelligence plc (NYSE:NIQ) to $11 from $16 while keeping an “Outperform” rating. The firm said the selloff was “hardly justified” by the actual results, noting some points to nitpick around decelerating organic growth, activations benefitting from backlog conversion, and a light Q2 profitability guide. BMO also pointed to positive attributes, including AI-related demand driving higher usage and the introduction of 30% long-term margin targets.
On May 15, 2026, UBS analyst Kevin McVeigh trimmed the firm’s price target on NIQ Global Intelligence plc (NYSE:NIQ) to $21 from $24 and kept a “Buy” rating, calling “incessant” AI concerns the driver of the 18% selloff. The same day, RBC Capital cut its target to $13 from $20 and kept an “Outperform” rating, noting that Q1 revenue and EBITDA beat estimates and the upper end of guidance, but said the lower target reflects a reduced valuation multiple due to a broader Info Services sector de-rating.
The results themselves were solid.
NIQ Global Intelligence plc (NYSE:NIQ) reported Q1 2026 revenue of $1,072.7 million, up 11.1% year-over-year, with organic constant currency growth of 5.1%, led by the Americas and EMEA. Adjusted EBITDA rose 19.1% to $224.8 million, with margin expanding 150 basis points to 21.0%. The company reaffirmed full-year 2026 guidance for 5.0% to 5.3% OCC revenue growth and a 23.5% to 23.8% adjusted EBITDA margin.
NIQ Global Intelligence plc (NYSE:NIQ) is a consumer intelligence and analytics software company. It provides data measurement, market research, and AI-driven insights to retailers and consumer packaged goods companies worldwide.
7. Bilibili Inc. (NASDAQ:BILI)
Bilibili Inc. (NASDAQ:BILI), with upside potential of 74.5%, ranks among the under-the-radar stocks with massive upside for 2026.
With Bilibili Inc. posting a profitable first quarter, the stock earned an analyst price target increase as the company strengthened its case for sustained growth.
On May 19, 2026, Macquarie analyst Ellie Jiang raised her price target on Bilibili Inc. to $30 from $29.10 and kept an “Outperform” rating. Jiang cited rapid advertising growth and diverse sector contribution as the drivers behind a strong Q1. On the games side, the firm acknowledged a high base effect but said a healthy new title pipeline toward Q4 should support a more optimistic outlook. Macquarie added that an AI-related R&D pickup should be partially offset by cost management.
The analyst note followed Q1 2026 results reported by Bilibili Inc.. Total net revenues came in at $1.08 billion, up 7% year-over-year. Advertising revenue led the way, rising 30% to $375.3 million, driven by improved ad product offerings and enhanced efficiency. Mobile games revenue fell 12% to RMB1.52 billion ($220.7 million), reflecting the high base from San Guo: Mou Ding Tian Xia’s exceptional performance a year earlier.
Gross profit margin reached 37.1%, marking the 15th consecutive quarter of expansion. Adjusted net profit rose 62% to RMB585.4 million ($84.9 million), with adjusted net profit margin improving to 7.8% from 5.2% a year earlier. Bilibili Inc. returned to net profitability, reporting net profit of RMB202.0 million ($29.3 million) versus a net loss of RMB10.7 million in the same period of 2025.
Average DAUs grew 8% to 115.2 million, with average daily time spent rising 11 minutes year-over-year to 119 minutes.
Bilibili Inc. is a Chinese entertainment services company offering digital content, advertising services, and IP derivatives. Founded in 2009, the company also deals in development activities, e-commerce business, and game distribution activities.
6. Alumis Inc. (NASDAQ:ALMS)
With an analyst consensus upside of 79.4%, Alumis Inc. (NASDAQ:ALMS) ranks among the under-the-radar stocks with massive upside for 2026.
Alumis Inc. drew three analyst price target raises after reporting Q1 results and advancing its envudeucitinib pipeline toward a pair of major readouts.
On May 19, 2026, Chardan raised its price target to $40 from $38 and kept a “Buy” rating, citing updated pricing assumptions for envudeucitinib, modest changes in psoriasis penetration estimates, and updated financials after Q1 results. On May 15, 2026, Wells Fargo raised its target to $51 from $49 and kept an “Overweight” rating, arguing the Street-implied probability of success for envudeucitinib’s Phase 2b in systemic lupus erythematosus is too low, creating a favorable risk/reward setup ahead of the Q3 readout. Also on May 15, 2026, Guggenheim analyst Yatin Suneja raised the firm’s target on Alumis Inc. to $34 from $32 and kept a “Buy” rating, with the higher target reflecting the updated cash position following Q1 results.
Those updates followed Alumis Inc.’s Q1 2026 report on May 14, 2026.
Alumis Inc. ended the quarter with $569.5 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the fourth quarter of 2027. Net loss narrowed to $93.1 million from $99.0 million a year earlier. R&D expenses fell to $81.5 million from $96.6 million, primarily due to lower clinical trial costs following completion of enrollment for the pivotal ONWARD1 and ONWARD2 trials.
On the pipeline side, Phase 3 envudeucitinib data presented at the 2026 American Academy of Dermatology meeting showed PASI 90 responses of 68.0% and 62.1%, and PASI 100 responses of 41.0% and 39.5% by Week 24.
Alumis Inc. remains on track for an NDA submission in Q4 2026 and a potentially pivotal Phase 2b SLE topline readout in Q3 2026.
5. MakeMyTrip Limited (NASDAQ:MMYT)
MakeMyTrip Limited (NASDAQ:MMYT), with 74.3% upside potential, ranks among the under-the-radar stocks with massive upside for 2026.
Two analysts lowered their price targets on MakeMyTrip Limited after Q4 fiscal 2026 results, citing geopolitical headwinds and estimate resets, even as both kept bullish ratings on the stock.
On May 20, 2026, Citi analyst Vijit Jain cut the firm’s price target on MakeMyTrip Limited to $70 from $80 while keeping a “Buy” rating. Jain noted that the adjusted EBIT of $46 million came in 2% ahead of his estimates, with constant currency growth in gross bookings and adjusted revenues at 5% and 13% year-over-year, respectively. The firm said it is lowering estimates to factor in the prolonged impact of the geopolitical situation, and now builds in 3% and 6% year-over-year growth in gross booking value for Q1 and full-year fiscal 2027, respectively.
Those results came from MakeMyTrip Limited’s Q4 fiscal 2026 earnings call on May 19, 2026. Management said the quarter was impacted by the West Asia conflict, which weighed on westbound international travel and pushed up domestic airfares. Despite that, the company reported full-year fiscal 2026 gross bookings of $10.4 billion and IFRS revenue growth of 10.7% in constant currency. Full-year adjusted operating profit margin expanded to 1.82% of gross bookings from 1.71% in fiscal 2025. The company ended the quarter with cash and equivalents of over $782 million. Management said it remains cautiously optimistic and flagged continued near-term uncertainty from the conflict.
Ahead of the results, Goldman Sachs analyst Manish Adukia cut the firm’s price target to $80 from $117 on May 8, 2026, while keeping a “Buy” rating on MakeMyTrip Limited. Adukia cited steady estimate downgrades through fiscal 2026, demand headwinds, INR depreciation, AI disruption concerns, a potential India listing, and convertible bond redemption worries as factors weighing on the stock’s multiple.
Founded in 2000 and headquartered in Gurgaon, India, MakeMyTrip Limited operates a leading online travel platform offering airline tickets, hotel reservations, holiday packages, and rail and bus bookings. Its scale, expanding inventory, and strong brand recognition position it to benefit from sustained growth in India’s travel and tourism sector.
4. BETA Technologies, Inc. (NYSE:BETA)
With an analyst consensus upside of 90.9%, BETA Technologies, Inc. (NYSE:BETA) ranks among the under-the-radar stocks with massive upside for 2026.
Two analysts trimmed their price targets on Beta Technologies (BETA) while holding onto their bullish ratings, even as the stock sits 40% lower year-to-date.
On May 20, 2026, BTIG cut its price target on BETA Technologies, Inc. to $33 from $40, keeping a “Buy” rating.
The firm cited revised delivery expectations as the driver of the reduction. BTIG noted BETA Technologies, Inc. holds a dominant position on the eVTOL Integration Pilot Program initiative, with awards across seven of the eight projects, representing the most of any original equipment manufacturer. The firm said executing on those awards will pull forward labor and materials spend, but added that the incremental investment meaningfully de-risks the path to commercialization and could accelerate commercial readiness by approximately one year. BTIG said the developments further reinforce Beta Technologies’ leadership in Advanced Air Mobility.
On May 18, 2026, Citi analyst John Godyn lowered the firm’s price target on BETA Technologies, Inc. to $25 from $33, also keeping a “Buy” rating.
Godyn said the firm updated models across the aerospace and defense sector and does not expect an “immediate V-shaped rally” without a resolution to the Middle East conflict. Citi still sees buying opportunities following recent selloffs, expecting the aerospace group to rally first, followed by defense.
BETA Technologies, Inc. develops and manufactures electric aircraft platforms and propulsion systems in the United States, including electric aircraft, advanced propulsion systems, charging infrastructure, and related components for the aviation industry.
3. Ondas Inc. (NASDAQ:ONDS)
With an analyst consensus upside of 115.2%, Ondas Inc. (NASDAQ:ONDS) ranks among the under-the-radar stocks with massive upside for 2026.
Ondas Inc. drew fresh analyst support after announcing its acquisition of Omnisys, an Israeli AI-powered defense software developer.
On May 19, 2026, Needham reiterated a “Buy” rating and $23.00 price target on Ondas Inc., calling the deal one of Ondas’ most strategically significant transactions to date. The firm said the acquisition adds a software orchestration layer that transforms Ondas’ portfolio into a fully integrated multi-domain autonomous warfare platform. Needham estimates Omnisys could generate $30 million to $40 million in pro forma 2026 revenue, with greater upside in 2027 as Ondas scales adoption across allied markets.
The analyst note followed Ondas Inc.’s announcement on May 18, 2026, that it had entered into a definitive agreement to acquire 100% of Omnisys Ltd.
The deal closed on May 21, 2026, with Ondas Inc. paying approximately $196.6 million in common stock, structured through shares issued at closing, escrowed stock, and additional stock consideration paid in staged installments. Sellers are subject to daily trading volume limits on share sales, and Ondas has granted registration rights to enable future resale under U.S. securities rules.
Omnisys develops the Battle Resource Optimization (BRO) platform, a vendor-agnostic AI software suite with more than 25 years of operational deployment in advanced defense environments, including complex multi-layer air defense operations. The BRO platform integrates data across sensors, command-and-control systems, and autonomous assets to support real-time mission planning, resource optimization, and battlefield decision-making.
CEO Eric Brock said BRO is a “proven, battle-tested software platform” that will strengthen Ondas Inc.’s ability to integrate into existing customer infrastructures and deliver scalable solutions for global defense markets.
Ondas Inc. provides autonomous systems, robotics, counter-drone technologies, private wireless networks, and mission-critical defense and security platforms.
2. Legend Biotech Corporation (NASDAQ:LEGN)
Legend Biotech Corporation (NASDAQ:LEGN), with upside potential of 105.7%, ranks among the under-the-radar stocks with massive upside for 2026.
With continued CARVYKTI growth fueling a strong first quarter, Legend Biotech Corporation is nearing adjusted profitability this year, drawing attention from multiple analysts.
On May 13, 2026, RBC Capital analyst Leonid Timashev raised the firm’s price target on Legend Biotech Corporation to $64 from $62 and kept an “Outperform” rating following better-than-expected Q1 results. Timashev called it a good quarter for CARVYKTI, citing increasing penetration into earlier treatment lines, expansion into the community setting, and limited competitive pressure. HC Wainwright and Morgan Stanley also reiterated bullish ratings on the stock following the quarter.
Those analyst updates followed Legend Biotech Corporation’s Q1 2026 results reported on May 12, 2026.
CARVYKTI net trade sales reached approximately $597 million, up 52% year-over-year, with U.S. sales growing 36% and ex-U.S. sales surging more than 200%. Total revenue came in at $305 million, with collaboration revenue from the Janssen partnership rising 61% to $298.4 million. Net loss narrowed to $54.3 million from $101.0 million a year earlier. Adjusted net loss improved to $10.5 million from $27.0 million, with Legend Biotech Corporation’s management reaffirming guidance for company-wide adjusted profitability in 2026.
CARVYKTI is now approved in 18 global markets across more than 300 treatment sites. Legend Biotech Corporation reported a 99% manufacturing success rate and a median turnaround time of approximately 29 days. Gross margin on net product sales declined to 41% from 57% the prior quarter, due to one-time expenses tied to manufacturing capacity expansion. CFO Carlos Santos said that without that charge, the company would have been profitable on an adjusted basis.
Cash, cash equivalents, and time deposits stood at approximately $835 million with no long-term debt.
Legend Biotech Corporation is a commercial-stage biopharmaceutical company that develops innovative therapies. Being an end-to-end cell therapy company, they focus on medication for serious diseases such as hematologic malignancies and solid tumors.
1. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
With an analyst consensus upside of 126.9%, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) ranks among the under-the-radar stocks with massive upside for 2026.
Crinetics Pharmaceuticals, Inc. drew fresh analyst attention after multiple updates tied to the rollout of PALSONIFY and the company’s broader endocrine pipeline.
On May 11, 2026, Oppenheimer lowered its price target on Crinetics Pharmaceuticals, Inc. to $84 from $87 while maintaining an “Outperform” rating following quarterly results.
The firm pointed to continued enrollment in the Phase 3 carcinoid syndrome study and ongoing pivotal and Phase 2 trials for atumelnant in adult and pediatric congenital adrenal hyperplasia (CAH), with a Phase 2/3 study in ACTH-dependent Cushing’s syndrome expected to begin soon. Oppenheimer also said it is watching for initial clinical data from CRN09682 in neuroendocrine tumors later this year.
That followed Crinetics Pharmaceuticals, Inc.’s May 7, 2026, first-quarter report, which showed revenue rising to $10.7 million from $0.4 million a year earlier, including $10.3 million in net product revenue from PALSONIFY. The company received 232 enrollment forms during the quarter, while 263 unique healthcare providers prescribed the treatment within its first two quarters on the market. About 70% of patients on PALSONIFY at quarter-end were receiving reimbursed therapy.
Meanwhile, Citizens lowered its price target on Crinetics Pharmaceuticals, Inc. to $95 from $97 on May 8, 2026, while keeping an “Outperform” rating, citing PALSONIFY’s expanding prescriber adoption and improving reimbursement trends.
Crinetics Pharmaceuticals, Inc. ended the quarter with $1.3 billion in cash, cash equivalents, and investment securities and maintained its 2026 GAAP operating expense guidance of $600 million to $650 million.
Crinetics Pharmaceuticals, Inc. is engaged in developing and marketing innovative treatments for rare endocrine diseases and endocrine-related tumors. The company offers a range of therapies that are currently in different stages of clinical trials. These include Paltusotine, Atumelnant, CRN09682, oral GLP-1, and GIP nonpeptide.
READ NEXT: 9 Best Cloud Stocks to Buy as Azure Growth Hits 40% and 10 Best Nuclear Energy Stocks to Buy as SMRs Go Mainstream.
